Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

(2010) S-J Dawson et al.   BRITISH JOURNAL OF CANCER

Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy

(2010) Kyubo Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

(2008) Susanne Møller et al.   ACTA ONCOLOGICA

Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy

(2008) Qifeng Yang et al.   BREAST CANCER RESEARCH AND TREATMENT